The role of secondary cytoreductive surgery in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers: A comparative effectiveness analysis

Oncologist

Volumn 17, Issue 6, 2012, Pages 847-855

  Chuang, Chi Mu ^a,b   Chou, Yiing Jeng ^b   Yen, Ming Shyen ^a   Chao, Kuan Chong ^a   Twu, Nae Fang ^a   Wu, Hua Hsi ^a   Wen, Kuo Chang ^a   Chen, Yi Jen ^a   Wang, Peng Hui ^a   Lai, Chung Ru ^a   Chou, Pesus ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Instrumental variable; Ovarian cancer; Propensity score; Secondary cytoreductive surgery

Indexed keywords

ADULT; ANASTOMOSIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); COLOSTOMY; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GASTRECTOMY; HUMAN; ILEOSTOMY; INSTRUMENTAL VARIABLE ANALYSIS; JEJUNOSTOMY; LIVER RESECTION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS RESECTION; PERITONEUM CANCER; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPLENECTOMY; UTERUS CANCER;

BODY MASS INDEX; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; OVARY; PERITONEAL NEOPLASMS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862873222     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0373     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A metaanalysis. J Clin Oncol 2002;20:1248-1259.
3. Berek JS, Hacker NF, Lagasse LD et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983;61:189-193.
4. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: Chance, not choice. Lancet 2002;359:515-519.
5. Carboplatin and paclitaxel with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. Available at http://clinicaltrials.gov/ ct2/show/NCT00565851. Accessed February 1, 2012.
6. Study comparing tumor debulking surgery versus chemotherapy alone in recurrent platinum-sensitive ovarian cancer (DESKTOP III). Available at http:// clinicaltrials.gov/ct2/show/NCT01166737. Accessed February 1, 2012.
7. Segna RA, Dottino PR, Mandeli JP et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. Clin Oncol 1993;11:434-439.
8. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-153.
9. Gadducci A, Iacconi P, Cosio S et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000;79:344-349.
10. Tay EH, Grant PT, Gebski V et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002;99:1008-1013.
11. Onda T, Yoshikawa H, Yasugi T et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: Proposal for patients selection. Br J Cancer 2005;92:1026-1032.
12. Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106:1933-1939.
13. Salani R, Santillan A, ZahurakMLet al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome. Cancer 2007;109:685-691.
14. Harter P, Hahmann M, Lueck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: Exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009;16:1324-1330.
15. Sehouli J, Richter R, Braicu EI et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol 2010;102:656-662.
16. Woelber L, Jung S, Eulenburg C et al. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol 2010;36:583-588.
17. Goto T, Takano M, WatanabeAet al. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers. Int J Gynecol Cancer 2011;21:263-268.
18. Congressional Budget Office. Research on the Comparative Effectiveness of Medical Treatments: Issues and Options for an Expanded Federal Role. Pub. No. 2975. Washington, DC: U.S. Congress, 2007.
19. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008;61: 344-349.
20. Psaty BM, Koepsell TD, Lin D et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999;47:749-754.
21. Sturmer T, Joshi M, Glynn RJ et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59:437-447.
22. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000;29:722-729.
23. Dickman PW, Sloggett A, Hills M et al. Regression models for relative survival. Stat Med 2004;23: 51-64.
24. Sturmer T, Schneeweiss S, Brookhart MA et al. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: Nonsteroidal anti-inflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005;161:891-898.
25. Guo S, Fraser MW. Propensity Score Analysis: Statistical Methods and Applications. Chapel Hill, NC: Sage Publications, 2010.
26. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassifcation on the propensity score. J Am Stat Assoc 1984;79:516-524.
27. Weitzen S, Lapane KL, Toledano AY et al. Principles for modeling propensity scores in medical research: A systematic literature review. Pharmacoepidemiol Drug Saf 2004;13:841-853.
28. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects:AMonte Carlo study. Stat Med 2007; 26:734-753.
29. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
30. Brookhart MA, Wang PS, Solomon DH et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006;17:268-275.
31. Rassen JA, Schneeweiss S, Glynn RJ et al. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Am J Epidemiol 2009;169:273-284.
32. Stock JH, Yogo M. Testing for weak instruments in linear IV regression. In Andrews DWK, Stock JH, eds. Identification and Inference for Econometric Models: Essays in Honor of Thomas Rothenberg. New York: Cambridge University Press, 2005;80-108.
33. Schneeweiss S. Sensitivity analysis an external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303.
34. Sturmer T, Jonsson Funk M, Poole C et al. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology 2011;22: 298-301.
35. Peduzzi P, Concato J, Kemper E et al. A simulation study of the number of events per variable on logistic regression analysis. J Clin Epidemiol 1996;49: 1373-1379.
36. Harrell FEJ, Lee KL, Califf RM et al. Regression modeling strategies for improved prognostic prediction. Stat Med 1984;3:143-152.
37. Pizer SD. An intuitive review of methods for observational studies of comparative effectiveness. Health Serv Outcomes Res Methodol 2009;9:54-68.
38. Bellamy S, Lin J, Have T. An introduction to causal modelling in clinical trials. Clin Trials 2007;4:58-73.
39. Albano JD, Ward E, JemalAet al. Cancer mortality in the United Status by education level and race. J Natl Cancer Inst 2007;99:1384-1394.
40. Kalachand R, Hennessy BT, Markman M. Molecular targeted therapy in ovarian cancer: What is on the horizon. Drugs 2011;71:947-967